Richard Law

Richard Law serves as Chief Business Officer at HAYA Therapeutics. HAYA Therapeutics operates in the research sector with approximately 57.0 employees. The company is headquartered in Oxford, England. To date, HAYA Therapeutics has raised 45035083.0 in total funding, with the most recent round being Seed.

Industry & Role Insights

• • MessageCEO tracks 2,961 executives in the research sector.
• • We have verified contacts for 2 executives at HAYA Therapeutics.
• • 10,137 executive contacts are available in England.
• • Our database includes 201,469 c suite-level executives.

Outlook Amazon AWS Mobile Friendly Google Font API Google Tag Manager Viewpoint

lncrna genomic medicines fibrosis biotechnology research precision medicine rna therapies dark genome long non-coding rnas disease reprogramming therapeutic target discovery oncology treatments fibrosis treatment cancer immunotherapy cardiovascular therapies anti-fibrotic therapies drug development clinical trials therapeutics for chronic diseases diagnostic platforms cell-specific treatments multifactorial disease targeting computation biology biotechnology lncrna feature discovery environmental signal integration disease modifying therapy rna-guided therapeutics regulatory genome tumor microenvironment clinical candidate selection biomarkers oncology pipeline contract research translational studies genome modulation technologies proprietary tools multi-omic data analysis biopharma partnerships therapeutic innovation medical advisory boards disease associated gene pathways rna-targeting modalities precision therapeutics clinical research sustainable growth biotech funding rna-based diagnostics antisenese oligonucleotide technology innovative drug candidates dark matter of the genome cell state catalogue therapeutic pipeline research collaborations biopharmaceutical innovative therapies disease-modifying therapeutics lncrnas heart failure fibrotic diseases chronic diseases metabolic disorders obesity antisense oligonucleotides tissue-selective therapies cell-state reprogramming collaborative research eli lilly partnership genetic medicine unmet medical needs advanced therapeutics pre-clinical development healthcare innovation switzerland u.s. operations strategic partnerships health care health wellness & fitness hospital & health care

EA

Eric Adam Chief Operating Officer at HAYA Therapeutics

SN

Srikanth Nandiraju Chief Technology Officer at 1Cell.Ai Inc.

SD

Surinnder Dang Chief Business Officer at 1Cell.Ai Inc.

M

Mark Chief Executive Officer at 23Strands

IT

Ilia Tikhomirov Chief Executive Officer at 35Pharma

Outreach Guidance — research Sector

Executives like Richard Law in the research sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at HAYA Therapeutics.

How do I reach Richard Law directly?

Richard Law's verified email address is available to MessageCEO Pro subscribers. They currently serve as Chief Business Officer at HAYA Therapeutics. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Richard Law work for?

Richard Law is Chief Business Officer at HAYA Therapeutics, a company in the research sector with 57.0 employees. The company is based in Oxford, England.

Can I pitch or sell to Richard Law?

As Chief Business Officer at HAYA Therapeutics, Richard Law is a key decision-maker in the research sector. MessageCEO Pro gives you verified email to reach Richard Law directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Richard Law in?

Richard Law works in the research industry as Chief Business Officer at HAYA Therapeutics. MessageCEO provides verified contact information for executives across all major industries.

Is Richard Law's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Richard Law's profile is kept up-to-date with the latest available information.

Last updated: May 13, 2026